Book Description:
Predictive, preventive and personalized medicine offers great promise for the future practice of medicine. Essential components of this approach include well-organized population screening protocols utilizing novel diagnostic biomarkers of disease states, targeted prevention of common human pathologies, optimal treatment planning and personalized medicine thereby resulting in substantial improvement of the quality of life. This approach also offers the advantage of delivering care at potentially reduced costs to the population at large thereby addressing social and ethical issues related to access to and affordability of health care. Consequently, conventional medicine and new branches of biomedicine are currently challenging many issue-related questions: Should molecular diagnostic approaches be considered complementary or substitutive measures to conventional approaches? How reliable are biomarkers for any given pathology? How to distinguish between the highly predictive power of innovation and quackery in diagnostics? How to overcome currently well-recognizable (inter)national barriers in knowledge transfer? How to correctly educate the new generation of experts in bio- and predictive medicine? The book addresses these highly relevant issues and provides some clues for plausible solutions.

The information presented in this book emphasizes the necessity of individualized patient treatment and provides compelling reasons as to why “across-the-board” treatment is not warranted. Application of nutritional proteomics results in individualized optimal diet and may potentially restrict the epidemic scale of type 2 Diabetes mellitus. A broad distribution and a routine clinical utilization of these advanced technological approaches could enable a significant portion of the population to reach the 100-year age limit yet remaining vibrant in excellent physical and mental health and as actively contributing members of society.

The examples given in the book are based on well-recognized expertise, scientific publications and international patents. A panel of leading world experts and authorities of the international issue-related associations have contributed to the book by addressing relevant issues and topics such as model-based patient-care and individualized therapy-planning, reproductive medicine and postnatal diagnostics, early/predictive diagnosis and optimized treatment of cancer as well as the most frequent neurodegenerative disorders.

Table of Contents:
A. Introduction

Chapter 1. Predictive Medicine as the new philosophy in health care pp. 1-3
(Vincenzo Costigliola, The “European Medical Association”, Brussels, Belgium; Peter Gahan, Medical Faculty, Reinische Friedrich-Wilhelms-University of Bonn, Germany and Olga Golubnitschaja, King’s College, London, U.K.)

B. Advanced technologies in Predictive and Personalized Medicine

Chapter 2. The role and predictive power of cell cycle checkpoints in aging, cardiovascular, cancer, and neurodegenerative diseases pp. 7-29
(Olga Golubnitschaja, Univ. of Bonn, Germany)

Chapter 3. Circulating Nucleic Acids in Plasma and Serum: Roles in Diagnosis and Prognosis pp. 31-53
(Peter B Gahan, King’s College London, Department of Anatomy & Human Sciences, London, UK)

Chapter 4. Pharmacogenetics and prediction of drug response pp. 55-71 (Iris Grossman, Genetics, Research and Development, GlaxoSmithKline, North Carolina, USA)

Chapter 5. Prediction of Degeneration of Native and Bioprosthetic Aortic Valves pp. 73-101
(Kristina Yeghiazaryan, Dirk Skowasch, Gerhard Bauriedel, Dept. of Internal Medicine II - Cardiology, Rheinische Friedrich-Wilhelms-Univ. of Bonn, Germany; Dept. of Internal Medicine I - Cardiology, Hospital Meiningen, Germany; Hans H. Schild and Olga Golubnitschaja, Dept. of Radiology, Rheinische Friedrich-Wilhelms-University)

Chapter 6. Gene therapy and individualized medicine pp. 103-127 (Patrick T Harrison, Dept. of Physiology and BioSciences Institute, Univ. College Cork, Ireland; Rowan Flynn, Dept. of Medicine, Univ. of Washington, Seattle, USA and Ciaran M Lee, Dept. of Physiology and BioSciences Institute, Univ. College Cork, Ireland)

Chapter 7. Model-based patient care with a therapy imaging and model management system pp. 131-145
(Heinz Lemke, Technical Univ. of Berlin, Germany and Leonard Berliner, Weill Cornell Medical College of Cornell Univ., USA)

C. Diabetes Care: Risk factors, Prediction, Prevention, Therapy

Chapter 8. IDiabetes Mellitus pp. 147-150
(Olga Golubnitschaja)

Chapter 9. New tendencies in the epidemiology of Diabetes mellitus pp. 151-156
(Melanie Cebioglu Dept. of Radiology, Rheinische Friedrich-Wilhelms-University of Bonn, Germany and Olga Golubnitschaja)

Chapter 10. Diabetic Complications: Pathogenic Mechanisms and Prognostic Indicators pp. 157-182
Mahmood S. Mozaffari, Dept. of Oral Biology, Medical College of Georgia School of Dentistry, Augusta, Georgia; Rafik Abdelsayed, Dept. of Oral Health and Diagnostic Sciences, Medical College of Georgia School of Dentistry, Augusta, GA and
Stephen W. Schaffer, Dept. of Pharmacology, College of Medicine, Univ. of South Alabama, Mobile, Alabama)

Chapter 11. Potential predictive biomarkers for the dysfunction of ß-cells in type 2 diabetes pp. 183-212
(Jadranka Koehn and Dritan Turhani, , Dept. of Cranio- Maxillofacial and Oral Surgery, Medical Univ. of Vienna, Austria; Kurt Krapfenbauer, Novartis Institutes for Biomedical Research, Novartis Vienna, Austria)

Chapter 12. Advanced technologies for prediction of secondary complications in Diabetes mellitus pp. 213-229
(Olga Golubnitschaja)

Chapter 13. Prevalence, targeted treatment and prevention of eye disorders in Diabetes pp. 231-246
(Tatjana Josifova and Paul B Henrich, University Hospital,Basel, Switzerland; Wolfgang Schrader, Maximilians Hospital Nürnberg, Germany)

Chapter 14. Diabetes mellitus as a risk factor for cancer: Is predictive diagnosis possible? pp. 247-262
(Melanie Cebioglu and Hans H Schild, Dept. of Radiology, Rheinische; Friedrich-Wilhelms-University of Bonn, Germany; Olga Golubnitschaja)

Chapter 15. Multiple drug resistance associated with function of ABC-transporters in Diabetes mellitus: Molecular mechanism and clinical relevance pp. 263-283
(Jadranka Koehn, Medical Univ. of Vienna; Michael Fountoulakis, Roche Center for Medical Genomics, F. Hoffmann-La Roche, Basel, Switzerland; Proteomics Research Unit, Biomedical Research Foundation, Academy,Athens, Greece; Kurt Krapfenbauer,
Novartis Institutes for Biomedical Research, Novartis Vienna, Austria)

Chapter 16. Advanced drug delivery systems in Diabetes treatment pp. 285-303
(Jorge F. J. Coelho, Institute of Biomedical Research in Light and Image, Univ. of Coimbra, Portugal; Paula Ferreira, Univ. of Coimbra, Portugal; Department of Health Sciences, Portuguese Catholic Univ., Viseu, Portugal; Ana C. Fonseca, Univ. of Coimbra, Portugal and Alexandre F. Fernandes, Institute of Biomedical Research in Light and Image, Univ. of Coimbra, Portugal, Paulo Pereira, Institute of Biomedical Research in Light and Image, Univ. of Coimbra, Portugal; Raquel Seiça, Institute of Biomedical Research in Light and Image, Faculty of Medicine, University of Coimbra, Portugal and Maria H Gil, Rheinische Friedrich-Wilhelms-Univ. of Bonn, Germany)

D. Prediction and targeted treatment of neurodegenerative disorders

Chapter 17. Prediction and targeted prevention of Parkinson's and Alzheimer's diseases pp. 307-353
(Silvia Mandel, Eve Topf Center for Neurodegenerative Diseases Research, Faculty of Medicine, Technion, Haifa, Israel; Ilan Halperin, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel; Amos D Korczyn, Tel-Aviv Univ. Medical School, Ramat-Aviv, Israel; Micaela Morelli, Univ. of Cagliari, Italy)

Chapter 18. Multiple sclerosis related biomarkers pp. 355-373
(Marcel Stoop, Rogier Hintzen, Theo Luider, Department of Neurology, ErasmusMC, Rotterdam, The Netherlands)

Chapter 19. What are the biomarkers for Glaucoma? pp. 375-396
(Olga Golubnitschaja, Kristina Yeghiazaryan, Rheinische Friedrich-Wilhelms-Univ.of Bonn, Germany; Selim Orguel, Univ. Hospital Basel, Switzerland; Josef Flammer, Univ. Hospital Basel, Switzerland )

E. Prediction and targeted treatment of cancer

Chapter 20. Integrated diagnostics and personalized therapeutics in oncology pp. 399-431
(Jeffrey S. Ross, Albany Medical College, Albany, New York, USA)

Chapter 21. How realistic are non-invasive approaches in breast cancer prediction? pp. 433-446
(Michael Braun, Univ. of Bonn, Germany; Michael Fountoulakis, Roche Center for Medical Genomics, F. Hoffmann-La Roche, Basel, Switzerland; Proteomics Research Unit, Centre of Basic Research II, Biomedical Research Foundation, Academy of Athens, Greece; Kristina Yeghiazaryan; Hans H. Schild, Rheinische Friedrich-Wilhelms-Univ. of Bonn, Germany; Walter Kuhn,Univ. of Bonn, Germany and Olga Golubnitschaja)
-
Chapter 22. Are side-effects of irradiation predictable for treatment of breast cancer patients? pp. 447-456
(Kristina Yeghiazaryan, Michael Braun, Soulafa Mamlouk, Rheinische Friedrich-Wilhelms-Univ. of Bonn, Germany; Hans H. Schild, Rheinische Friedrich-Wilhelms-Univ. of Bonn, Germany and Olga Golubnitschaja)

Chapter 23. Prediction of pro-invasive potential in treated malignant gliomas: Engineering of clinical treatment pp. 457-470
(Daniela Trog, Kristina Yeghiazaryan, Winrich Breipohl, Hans H. Schild, Olga Golubnitschaja)
-
Chapter 24. Biomarker discovery in glioma by combined approach of laser microdissection and advanced mass spectrometry pp. 471-476 (Dana Mustafa, J M Kros Department of Pathology, ErasmusMC, The Netherlands; Theo M Luider, Department of Neurology, ErasmusMC, Rotterdam, The Netherlands)

F. Predictive Diagnosis in Reproductive Medicine and Pediatrics

Chapter 25. Proteomics-based prediction in prenatal diagnosis and reproductive medicine pp. 479-498
(George Th. Tsangaris, Biomedical Research Foundation, Academy of Athens, Greece; Aggeliki Kolialexi,Athens Univ. School of Medicine, Greece; George Spyrou, Biomedical Research Foundation, Academy of Athens, Greece Ariadni Mavrou, Academy of Athens, Greece; Michael Fountoulakis, R.F. Hoffmann-La Roche, Basel, Switzerland; Proteomics Research Unit, Biomedical Research Foundation, Academy of Athens, Greece)

Chapter 26. Birth asphyxia as the most frequent perinatal complication pp. 499-507
(Viktoriya Peeva, Rheinische Friedrich-Wilhelms-Univ. of Bonn, Germany; Kristina Yeghiazaryan and Olga Golubnitschaja)

Chapter 27. Potential targets for early diagnosis and neuroprotection in asphyxiated newborns pp. 509-525
(Kristina Yeghiazaryan; Viktoriya Peeva; Micaela Morelli, Univ. of Cagliari, Italy; Mario Herrera-Marschitz, Karolinska Institute, Stockholm, Sweden, Univ. of Chile, Santiago, Chile and Olga Golubnitschaja)

G. Informatics, Economics, Knowledge Transfer and Patents in Predictive Medicine

Chapter 28. Information systems as an essential component of prediction in the laboratory diagnostics pp. 529-548
(Marko Kapalla, Negentropic Systems, Ruzomberok, Slovakia and Dagmar Matušková, Alpha medical, Ruzomberok, Slovakia)

Chapter 29. Economic aspects and the role of insurance in predictive diagnostics pp. 549-558
(Walter R. Stahel, Research on Risk Management, The Geneva Association, Geneva, Switzerland, Univ. of Surrey, Guildford, UK and Christophe Courbage, Research on Health & Ageing, The Geneva Association, Geneva, Switzerland)

Chapter 30. Knowledge transfer and patenting strategy in predictive medicine pp. 559-569
(Kordula Kruber, PROvendis GmbH, Mülheim/Ruhr, Germany and Jürgen Walkenhorst, PROvendis GmbH, Mülheim/Ruhr, Germany)

Index